Press Releases

Press Releases

or

October 31, 2019
• Companies to Collaborate on the Commercialization of XGEVA ® (denosumab), KYPROLIS ® (carfilzomib), and BLINCYTO ® (blinatumomab) in China   • Companies to Jointly Develop 20 Amgen Oncology Pipeline Assets, with BeiGene Responsible for Development and Commercialization in China as Part of the